All In Biotech

Drug Trial Radar · NCT05984784

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

A Phase1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

13

Actual

Start

Aug 9, 2023

Primary completion

Apr 26, 2024

Study completion Apr 26, 2024

Sponsor

Lead sponsor
Inmagene LLCIndustry
Sponsor type
Industry
First posted
Aug 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.

Conditions

  • Atopic Dermatitis
  • Moderate-to-severe Atopic Dermatitis
  • AD

Interventions

  • PlaceboDrug

    Drug: Placebo Intravenous Infusion

  • IMG-007Drug

    Drug: IMG-007 Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of Adverse Events in ParticipantsTime frame: Adverse events were collected from baseline through the end of the study, a period of up to 24 weeks.

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Amicis Research Center

    Northridge, California

  • Amicis Research Center

    Valencia, California

  • Medical Research Center of Miami II Inc

    Miami, Florida

  • Optimal Research Sites

    Orange City, Florida

  • USF Carol and Frank Morsani Center for Advanced Healthcare

    Tampa, Florida

  • Revival Research Institute, LLC

    Troy, Michigan

  • Markowitz Medical, LLC

    New York, New York

  • Central Sooner Research

    Oklahoma City, Oklahoma

  • Paddington Testing Co, Inc

    Philadelphia, Pennsylvania

  • Centre de Recherche Saint-Louis (Québec)

    Québec, Canada

  • Brunswick Dermatology Center

    Fredericton, New Brunswick, Canada

  • DermEffects

    London, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.